Categories: News

Nexcelom Bioscience Launches the Cellaca™ MX at AACR

ATLANTA, April 1, 2019 /PRNewswire/ — Nexcelom Bioscience, a leading provider of cell counting and characterization products for the life science industry, announced the launch of the revolutionary high throughput, high-speed automated cell counter – Cellaca™ MX.

The Cellaca™ MX utilizes Nexcelom’s innovative cellular analysis technology for accurate cell sample concentration, viability and morphology measurements.  Features of the Cellaca™ MX include:

  • Brightfield and Fluorescence image cytometry
  • Cell Viability analysis using trypan blue OR fluorescent dyes
  • 24 samples imaged and processed in as quickly as 48 seconds
  • Only 25 µL cell sample required
  • 4 excitation light sources with 5 emission wavelengths for detection
  • SBS plate format
  • Automation-ready for robotic integration

According to Nexcelom CTO, Dr. Jean Qiu, the company is focused on enabling highly accurate cell counting at fast speeds in order to help accelerate other technology advancements. One such application is single-cell RNA sequencing to compare transcriptomes of single cells in determining disease mechanisms. A critical factor for successful high-quality, single-cell data is the quality of cells and the cell number per experiment. It is important to not only know the cell number and health but also the specific cell type in a heterogeneous population.  Another area that will see a huge benefit is the field of Cell Therapy.

Fast analysis for cell count and viability, using a very small amount of sample, makes Cellaca™ MX suitable for droplet-based single-cell transcriptome analysis, utilized to analyze primary samples from human and animal models.

Dr. Kristie Barth, an Immunologist at Evelo Biosciences, commented “The Cellaca™ MX has dramatically reduced sample processing time for our ex vivo preparations.  What used to take us 5 people and 7 hours, now takes us only 3 people and 4 hours to process the samples, count the cells and plate them for downstream assays.  Not only has the Cellaca™ MX saved us time and increased our efficiency, but it also has improved our sample quality.  Cells no longer sit on ice waiting to be counted, making the data output for our proteomic, genomic, and flow cytometry applications more accurate.” 

About Nexcelom: Headquartered in Lawrence, MA, Nexcelom Bioscience LLC is a manufacturer of innovative Cellometer®, Cellaca™ MX, and Celigo® image cytometry products for cell analysis. Nexcelom’s solutions automate time-consuming procedures, enabling scientists to focus less on the process and more on the research results. Contact Nexcelom Bioscience at +1 978-327-5340 or visit www.nexcelom.com

Contact: Dr. Kapil Kumar, (978) 483-8191, kkumar@nexcelom.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/nexcelom-bioscience-launches-the-cellaca-mx-at-aacr-300821303.html

SOURCE Nexcelom Bioscience

Staff

Recent Posts

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…

50 minutes ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…

51 minutes ago

The National Children’s Cancer Society Awarded $1,000 Grant From Kars4Kids

This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…

54 minutes ago

Honeycomb Clinic Positions for Public Offering

Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…

54 minutes ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…

54 minutes ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease

MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…

54 minutes ago